CELLVIE presents at the Rejuvenation Startup Summit 2024 in Berlin

The Rejuvenation Startup Summit, brought to you by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry.

The summit brings together world-leading rejuvenation startups, members of the rejuvenation/longevity venture capital ecosystem, and the wider investment community.

It is the world’s largest in-person gathering of startups in the space.

Rejuvenation/Longevity biotech is a new, emerging field of medicine. It aims to prevent and reverse diseases of aging by addressing their common root cause, the aging process itself. Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production. These therapies not only aim to significantly extend the healthy human lifespan but also offer a groundbreaking new business model for approaching healthy longevity.

Dr. Alexander Schueller, cellvie's CEO and co-founder, was one of the distinguished speakers invited from longevity biotech start-ups. Dr. Alexander Schueller presented on the potential of mitochondria as a new treatment modality, not only for ischemia-reperfusion injury, but also for aging related degeneration. Loss of mitochondria function and mass has been reported in muscle degeneration and cellvie has been working to counter these developments with mitochondria transplantation.

Alex started by saying that at Cellvie "we are truly leveraging the therapeutic potential of mitochondria".

Alex's presentation at the Rejuvenation Startup Summit 2024 can be watched here:

About cellvie AG

Founded in the United States and headquartered in Zürich, Switzerland, Cellvie is pioneering the development of cell-based medicines, harnessing the therapeutic potential of mitochondria. The company was established in 2018 by Drs. Schueller, McCully, del Nido, and Emani. Dr. McCully, a pioneer in mitochondrial augmentation and replacement at Harvard Medical School, laid the foundation for this innovative approach. Today, the Cellvie team is advancing this breakthrough treatment modality to address ischemia-reperfusion injury, aging, and other conditions. Since its inception, Cellvie has successfully expanded its team and operations near Zürich.

Further information can be found at www.cellvie.bio.

Back to news